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Abstract 
 
 The chemopreventive effects of resveratrol (RSV) on cancers, including prostate 
cancer, have been well documented; but the mechanisms are not well known. It has been 
reported recently that tensin, a matrix-adhesion protein, which is greatly down-regulated 
in prostate cancer, has been induced by RSV in several cancer cell lines.  
 In order to know if RSV up-regulates tensin in prostate cells, we first treated 
LNCaP cells with RSV and demonstrated that tensin mRNA levels were upregulated by 
RSV in a time and dose dependent manner. Since LNCaP cells are androgen receptor 
(AR) positive and previous findings have shown that RSV down-regulates AR protein 
levels as well as its transcriptional activity, we were interested to see whether RSV 
effects on tensin are AR dependent.  When LNCaP cells were treated with androgen 
(R1881), tensin mRNA levels were down-regulated and this effect was counteracted by 
RSV. These results strongly suggest that RSV upregulation of tensin mRNA at least 
partially involves AR. To further confirm its AR dependency, we used a previously 
established stable AR(+) expressing HeLa cell line in a series of experiments; with the 
AR(-) HeLa cell line serving as a negative control.  Similar to what we saw in LNCaP 
cells, tensin mRNA levels were upregulated in the AR(+) cells, and RSV counteracted 
androgen induced downregualtion of tensin mRNA levels. However, this effect was not 
shown in the AR(-) cells.  
 In summary, we have demonstrated that RSV up-regulates tensin expression in 
prostate cancer cells and this effect is, at least in part, AR dependent. Together with our 
previous observations, we provided further evidence at both cellular and molecular levels 
that RSV may serve as a preventative and therapeutic agent for prostate cancer. 
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Introduction 
Prostate cancer is one of the biggest threats to men’s health in the Western world 
and is the most frequently diagnosed cancer among men in the United States (Jones, 
DePrimo, Whitfield, & Brooks, 2005). It also accounts for the second largest number of 
male cancer deaths in the U.S. (Jemal et al., 2004; Jemal et al., 2005). The mechanisms of 
this disease are not yet completely understood, although both genetic and environmental 
factors are known to be involved in its development. In addition to age, race, 
environmental factors, and even diet, family history also seems to play a large role in the 
development of prostate cancer. Men with a family history of prostate cancer have a 
significantly greater risk of developing prostate cancer than those with no such history 
(Johns & Houlston, 2003). Age seems to be an important risk factor for this cancer in 
particular. In fact, 90% of males develop some form of prostatic disease between the ages 
of 40 and 90 (Chatterjee, 2003). As people are living longer, more men will be afflicted 
with this disease. Because of this, it is becoming more important than ever to find better 
treatments and a potential cure for prostate cancer.  
There are two types of prostate cancer; androgen-dependent and androgen-
independent prostate cancer. The earlier stages of prostate cancer are usually androgen-
dependent. At this stage, tumor growth is reliant on androgen. Later stages of the cancer 
are usually termed androgen-independent, and are not reliant on androgen to cause 
abnormal growth (Agoulnik & Weigel, 2006). Androgens are hormones that are 
important in many biological functions including fetal development and male 
development during puberty. They are hydrophobic and have the ability to readily diffuse 
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through cell membranes. The biological effects of androgens are mediated through a 
transcriptional factor called the androgen receptor (AR) (Heinlein & Chang, 2004).  
 
Androgen Receptor (AR)    
AR is a 110-kDa phosphoprotein, a member of the nuclear receptor family of 
ligand-activated transcriptional factors. Without androgen, AR is located in the 
cytoplasm, bound by heat shock proteins. When androgen binds to AR, the receptor 
disassociates from the heat shock proteins and translocates into the nucleus. Once in the 
nucleus, the receptor binds to specific DNA sequences called androgen response elements 
(AREs) on the promoters of the target genes and recruits a series of co-activators or co-
repressors in order to enhance or repress the expression of certain genes. The activity of 
AR is dependent not only on levels of hormone and receptor, but also on the levels and 
activities of co-activators/co-repressors (Agoulnik & Weigel, 2006) (Fig1). Intact AR 
signaling appears to be required for the initiation and growth of prostate cancer. This 
signaling has been found in all types of prostate cancers, primary and metastatic, in both 
androgen-dependent and androgen-independent prostate cancers. In androgen-dependent 
prostate cancer, the binding of androgen to AR stimulates the cancerous growth. AR 
continues to be expressed in androgen-independent tumors and AR signaling remains 
functional, but androgen-independent prostate cancer does not depend on androgen for 
growth.  
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Androgen-independent prostate cancers have demonstrated a variety of AR 
alterations that include AR amplification, point mutation, and changes in expression of 
AR co-regulatory proteins. These changes result in a "super AR" that can respond to 
lower concentrations of androgens or to a wider variety of agonistic ligands (Taplin & 
Balk, 2004). 
 
 
 
 
   
Figure 1: Molecular Activation of androgen receptor (AR) 
AR is typically found in its inactive form, bound to heat shock proteins in the cytoplasm. 
When AR binds to androgen, such as, testosterone, the heat shock proteins dissociate, and 
AR translocates into the nucleus. AR then binds to AREs on the DNA and recruits co-
activators (TAFs, TBP, GTFs). This enables androgen to have various biological effects 
(www.endotext.org/male/male3/index.html).  
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Co-activators and co-repressors of AR also play a role in the formation of prostate 
cancer. Co-activators of AR include a series of proteins which exhibit a variety of 
enzymatic activity including histone acetyl transferase activity, methyltransferase 
activity, kinase activity, and ubiquitin ligase activity (Smith & O'Malley, 2004). 
Although the relative contributions of most of these proteins to AR action have not yet 
been determined, there is one fairly consistent finding that has been identified in ARs 
relative contribution to prostate cancer. This is that artificial overexpression of a variety 
of co-activators induce AR activity in the presence of a broad range of metabolites 
including ligands for the other receptors (estradiol), adrenal androgens, androgen 
metabolites, and anti-androgens. These findings may be a reflection of the ability of a 
variety of ligands to bind to AR and to induce nuclear localization and DNA binding. 
Over-expression of co-activators is one of the causes for anti-androgen resistance 
(Agoulnik & Weigel, 2006; Edwards & Bartlett, 2005). 
Another means of cell signaling that alters the activity of AR is through its effects 
on co-repressor activity. Co-repressors have characteristically been considered to be 
proteins that interact with antagonist-bound steroid receptors recruiting histone 
deacetylases. However, recent studies have indicated that co-repressors can reduce the 
activity of agonist-bound AR (Agoulnik et al., 2003). Elevated-MAP/ERK kinase kinase 
1 (MEKK1) activity through growth factor signaling induces phosphorylation of one co-
repressor, silencing mediator for retinoic acid and thyroid hormone receptor (SMRT), 
dissociation from nuclear receptors, and relocalization of the co-repressor to the 
cytoplasm (Jonas & Privalsky, 2004). Thus, activation of this cell signaling pathway 
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would not only reduce the effectiveness of antagonists but also enhance the activity of 
agonist bound receptor (Agoulnik et al., 2003).  
Although the AR is most frequently associated with increased expression of 
androgen-responsive genes, it is also know to repress expression of some genes.  In a 
global gene expression study using a Genechip microarray, Wang et al found 
that 858 genes were differentially regulated in LNCaP cells treated with the androgen 
(R1881) for 16 hours.  Of these, 784 genes were significantly up-regulated, while 74 
were significantly down-regulated (G. Wang, Jones, Marra, & Sadar, 2006). 
Due to the belief that the androgen receptor (AR) plays an important role in the 
development of prostate cancer, research has focused on AR in order to discover 
mechanisms for its actions in prostate cancer development (Agoulnik & Weigel, 2006). It 
is hoped that understanding the changes in AR signaling in prostate cancer will be a key 
to developing a more effective treatment, and perhaps even a cure for prostate cancer. 
Currently, there are limited ways to battle this disease. If diagnosed early enough, there 
are therapies that may improve prognosis. Surgery can be a successful but radical option. 
In this case, many men experience problems such as urinary incontinence after surgery 
which can result in a negative impact on the quality of life of patients (Seeni et al., 2008). 
Additionally hormone ablation therapy benefits about 80% of patients by retarding the 
progression of the disease, but may not be a solution (OH, 2002). It has also been 
reported that patients receiving this treatment may experience serious side effects 
including osteoporosis, anemia, fatigue, emotional distress, erectile dysfunction, and even 
the development of diabetes and cardiovascular disease (Herr & O'Sullivan, 2000; 
Holzbeierlein, McLaughlin, & Thrasher, 2004; Keating, O'Malley, & Smith, 2006; 
8 
 
Nelson, Lee, Gamboa, & Roth, 2008; Thompson, Shanafelt, & Loprinzi, 2003). In 
addition, almost all prostate cancers eventually develop into an aggressive, hormone-
independent form, with little hope for further intervention. (OH, 2002). Therefore, the 
best approach for combating prostate cancer is deterring its onset. This makes 
chemoprevention an attractive approach (Shi et al., 2009). 
Prostate cancer is a multifactorial disease and epidemiologic studies have 
suggested that nutrition plays an important role in carcinogenesis and that 30% of cancer 
morbidity and mortality can potentially be prevented with proper adjustment of diet 
(Hsieh & Wu, 1999). Several dietary factors such as lycopene, vitamin E, and resveratrol 
(RSV), have been considered as potential prostate cancer chemopreventive agents (Shi et 
al., 2009).   
 
Resveratrol  
 RSV (3,5,4’-trihydroxystilbene) is a polyphenol transhydroxystilbene that is 
found at high levels in grapes and red wines. Resveratrol is a relatively simple molecule 
that has beneficial effects on human health. It plays a role in the prevention of human 
pathological processes such as inflammation, atherosclerosis and carcinogenesis (Harada 
et al., 2007). RSV exhibits several potential chemopreventive activities in animal and cell 
models. This includes inhibition of pathways responsible for cell signaling, cell growth, 
and tumorigenesis such as the phosphoinositide 3-kinase (PI3K)/AKT pathway. In 
addition, RSV promotes the transcription of pro-apoptotic molecules such as FasL and 
BiM. Finally, RSV up-regulates tumor suppressor pathways such as phosphatase and 
PTEN, a tensin homolog (Q. Chen, Ganapathy, Singh, Shankar, & Srivastava, 2010). 
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Although the mechanism is unknown, studies have indicated that it has an important role 
in prostate cancer chemoprevention (Careri, Corradini, Elviri, Nicoletti, & Zagnoni, 
2003; Y. Wang, Catana, Yang, Roderick, & van Breemen, 2002). 
Previously, it has been seen that RSV down-regulates the expressions of both AR 
and AR target genes (Jones et al., 2005; Seeni et al., 2008; T. T. Wang et al., 2008). In 
vitro studies with PC3, an androgen-independent prostate cancer cell line, have shown 
that the RSV effects on AR activity are concentration dependent; AR activity is enhanced 
at low concentrations (0.1-10 M) of RSV and repressed at high concentrations (100 M) 
(Gao, Liu, & Wang, 2004). Recently, it was also reported that RSV represses AR target 
gene expression, at least partially, by enhancing AR degradation in a time- and dose-
dependent manner (Harada et al., 2007). Given RSV’s repressive effects on AR and AR’s 
significance in the development of prostate cancer, these studies support a role for RSV 
as a potential candidate for the treatment and prevention of prostate cancer.  
In 2005, Rodrigue et al searched RSV affected genes in the human 
erythroleukemic K562 cell line. After 24 hr incubation of K562 cells in the presence of 
50 m RV, a RFDD–PCR technique was used to identify 134 cDNA fragments of 100–
750 nucleotides. Among them, 62 were up-regulated and 72 down-regulated (Rodrigue et 
al., 2005). One specific gene that was markedly induced by RSV was tensin. This effect 
was also seen in MCF7, a human breast cancer cell line (Rodrigue et al., 2005).  
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Tensin (Tensin 1) 
Tensin 1 is a 220kDa protein whose integrin binding domain links it to a 
component of the extracellular matrix (ECM). It is a member of a family of tensin 
molecules that share similar structures. Tensin1 contains multiple actin binding domains 
and the interaction between tensin constitutes the site of anchorage of the actin filaments 
and is localized to integrin-mediated focal adhesions. Tensin1 also contains a 
phosphotyrosine-binding (PTB) domain. These interactions allow tensin to link actin 
filaments to integrin receptors. The N-terminal domain of tensin1 associates with protein 
phosphatase-1α (PP1α) and mediates PP1α localization to adhesions (H. Chen, Ishii, 
Wong, Chen, & Lo, 2000; Hall, Daugherty, Choi, Horwitz, & Brautigan, 2009; Lo, 
2004). 
 
 
 
 
Figure 2: Schematic structure of tensin. Functional and Structural domains are shown.  
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Tensin is broadly expressed in human tissues including heart, skeletal muscle, 
kidney, lung, small intestine, liver, colon, prostate, testis, and ovary (Lo, Yu, Degenstein, 
Chen, & Fuchs, 1997). In 1997, Chen et al generated mice lacking tensin expression and 
studied the growth of the mice. It was found that even though tensin is expressed broadly 
in mouse embryos and a variety of postnatal tissues, the tensin-null mice developed 
normally and appeared healthy for several months. However, while most of the tissues 
seemed to be normal in older mice, multiple cysts were detected in the kidney, an organ 
that normally expresses high levels of tensin. The progressive cyst formation led to 
kidney degeneration and the mice subsequently died from renal failure. These results 
demonstrated that tensin is not necessary for mouse embryogenesis, but is required for 
the maintenance of normal renal function (Lo et al., 1997). 
Knockout mice were also used to investigate the role of tensin in wound healing. 
In 2001, Ishii and Lo looked at tensin’s role in the process of skeletal muscle 
regeneration. Cardiotoxin was used to induce regeneration in the anterior tibial muscles 
of tensin-knockout and wild-type mice. The histological analyses shown that the 
regeneration process lasted longer in knockout than in wild-type mice. This indicates that 
tensin play an important role in wound healing (Ishii & Lo, 2001). Tensin is also the first 
cytoskeleton-associated protein found to contain a Src Homology 2 (SH2) domain. The 
SH2 domain may allow tensin to translate tyrosine kinase or other regulatory signals in to 
a direct effect on the structure of the cytoskeleton. By binding to actin filaments and 
tyrosine phosphorylated proteins, tensin may serve as a scaffold around which signaling 
complexes can be assembled and hence, link the cytoskeleton with the signal transduction 
pathways (Davis et al., 1991) 
12 
 
Another study examined the mechanism of tensin-promoted cell migration. In 
2003, Chen and Lo mapped the focal adhesion-binding (FAB) sites on tensin1 using 
deletion mutagenesis and transfection analysis. They then generated mutants that 
specifically inactivated the FAB sites without disrupting the binding to actin and 
phosphotyrosine (pTyr)-containing proteins. The mutants were introduced into cells in 
order to define the structural requirements for subcellular localization of the protein and 
to determine how it affected cell migration. Their results demonstrated that the 
localization of tensin1 to the focal adhesion site is a critical step in the regulatory process 
of cell migration. Also, because SH2 domains may mediate signals related to cell 
migration, they inactivated the SH2 domain and showed that this mutant abolished 
tensin-promoted cell migration, indicating that a functional SH2 domain is also required 
for tensin-mediated cell migration (H. Chen & Lo, 2003).  These studies found that tensin 
played major roles in cell migration, wound healing, muscle regeneration and renal 
functions and that tensin and its downstream signaling molecules may be targets for 
therapeutic interventions in renal disease, wound healing and cancer (H. Chen et al., 
2000; Lo, 2004) . 
Since these studies, there has been specific focus on tensin expression and cancer. 
Interestingly, it has been found that tensin expression is greatly suppressed in some 
cancer cells, especially prostate cancer cell lines (Lo, 2004). Recent discoveries have 
shown that an important function of tensin is its association with a RhoGAP protein, 
which is an evolutionary conserved protein domain of GTPase activating proteins 
towards Rho-like small GTPases. The specific RhoGAP protein that tensin associated 
with is known as Deleted in Liver Cancer-1 (DLC-1), which is a negative regulator of 
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tumor formation and plays a role in cell migration. This suggests that tensin may play an 
important role in tumor suppression and may serve as a checkpoint in cell growth. 
Furthermore, there have been studies done with various tensin mutants in hopes to 
understand its importance in cancer. In 2009, Hall et al transfected Human Embryonic 
Kidney cells (HEK293) to express DLC-1 alone or co-express DLC-1 with S-tag-tensin1 
wild type, or F302A, which is the mutant tensin that showed reduced association with 
DLC-1. As studied by cell migration and morphology, compared to the wild type, the 
cells with the mutant tensin showed increased migration and invasion. These findings 
suggest that tensin may serve as a checkpoint of cell migration (Hall et al., 2009). Based 
on these previous findings, it may be beneficial to upregulate tensin levels in cancer cells 
in order to further study tensin’s importance in cancer formation and its potential uses as 
a therapeutic agent.   
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Materials and Methods 
Cells, Cell culture and Treatment: 
 LNCaP and K562cells were obtained from American Type Culture Collection 
(Manassas, VA) and were maintained in Roswell Park Memorial Institute (RPMI, 
Cellgro, Mediatech, Inc, Herndon, VA) containing 10% fetal bovine serum (FBS) 
(Atlanta Biologicals, Lawerenceville, GA) and 1% antibiotics/antimycotics (Abx/Amx) 
(Gibco, Invitrogen Corporation, Carlsbad, CA). Cells were trypsinized from tissue culture 
dishes (Cellgro, Mediatech, Inc., Herndon, VA) and resuspended in RPMI containing 1% 
Abx/Amx and 10% FBS for maintenance and subculturing. Cells were incubated at 37°C 
and 4.7% CO2.  
 AR(+) cells were created by cloning the AR cDNA into the retroviral vector pOZ-
N and integrating it into the genome of AR-negative HeLa cells from American Type 
Culture Collection (Manassas, VA) (Shi et al., 2009).  The AR(-) cells were obtained 
from American Type Culture Collection (Manassas, VA). Both cell lines were 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, Cellgro, Mediatech, Inc, 
Herndon, VA) containing 10% fetal bovine serum (FBS) (Atlanta Biologicals, 
Lawerenceville, GA) and 1% antibiotics/antimycotics (Abx/Amx) (Gibco, Invitrogen 
Corporation, Carlsbad, CA). Cells were trypsinized from tissue culture dishes (Cellgro, 
Mediatech, Inc., Herndon, VA) and resuspended in DMEM containing 1% Abx/Amx and 
10% FBS for maintenance and subculturing. Cells were incubated at 37°C and 4.7% CO2.  
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Cell Treatment: 
Cells were treated with RSV from a 200mM stock solution (Sigma Aldrich, St. 
Louis MO), and R1881 from a 10 M stock solution (Sigma Life Sciences, St. Louis 
MO). 
 
Analysis of tensin mRNA levels: 
 Total RNA was purified from LNCaP, K562, AR(+), and AR(-) cells using 
RNeasy Plus Micro Kit (Qiagen, Germantown MD). For cDNA synthesis, 5ug of total 
RNA was reverse transcribed using random primers (Stratagene, La Jolla, CA) and 
Superscript II reverse transcriptase (Invitrogen Corporation, Carlsbad, CA). Tensin and 
GAPDH were amplified by PCR using the following specifically designed primers 
(Invitrogen Corporation, Carlsbad, CA). Tensin primers: Forward, 5’- 
CGAATAGCTATCAAGAAAATC-3’; Reverse, 3’-CCTCTGAGGATCTGGTAGAG-
5’; GAPDH primers: Forward, 5’-ACAGCCTCAAGATCATCAGCAA-3’; Reverse, 3’-
ACCACTGACACGTTGGCAGT-5’. 
The following PCR conditions were used routinely in a Genious thermal cycler 
(Techne Inc., Burlington, NJ): denatured at 95°C for 2 minutes followed by 30 cycles of 
95°C, 1 minute, 60°C, 1 minute, 72°C, 1 minute; and enzyme was inactivated by 
incubation of 72°C for 5 minutes. PCR products were analyzed on a 1% agarose gel 
containing 1% ethidium bromide, and visualized under ultraviolet light. 
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Cell Lysis and Western Blotting: 
 Cells were collected and lysed with EBC buffer containing 20mM Tris HCl (pH 
8.0), 125 mM EDTA, and 0.5% NP-40. Lysates were collected and centrifuged at 
maximum speed for 20 minutes, and the resulting supernatant was collected. Protein 
samples were quantified using Pierce BCA Protein Assay Kit (Thermo Scientific, USA). 
Protein samples were separated by SDS-PAGE electrophoresis, using 10% resolving gel 
and a 4% stacking gel. Proteins were then transferred to a nitrocellulose membrane using 
iBLot Dry Blotting System (Invitrogen Corporation, Carlsbad, CA). Proteins were 
stained with MemCode Reversible Stain Kit for Nitrocellulose Membranes (Pierce, 
Rockford IL). Immunoblotting was performed using Pierce Fast Western Blot Kit 
(Thermo Scientific USA) using Tensin (H-300) rabbit polyclonal IgG (5 g/mL) or AR 
(N-20) sc-816 rabbit polyclonal IgG (5 g/mL) (Santa Cruz, Santa Cruz CA). The blots 
were detected using Immun-Star WesternC Chemiluminescence Kit (Bio Rad, Hercules 
CA).  
 
Statistical Analysis: 
To determine if effects were significant, Statview Software was used to conduct a 
Bonferroni/Dunn ANOVA. P-values less than 0.05 were considered significant.  
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Results 
 RSV Up-regulates Tensin mRNA Levels in LNCaP Cells   
Based on previous reports that RSV upregulated tensin in different cancer cell 
lines, we tested whether RSV would have similar effects on tensin expression in prostate 
cancer cells. First, to serve as our positive control, we conducted an experiment similar to 
what was described by Rodrigue et al in 2005 (Rodrigue et al., 2005). Specifically, K562 
cells were treated with 100 M of RSV for 24 hrs and RT-PCR was used to determine 
levels of tensin mRNA. As expected, the RSV treatment upregulated tensin mRNA levels 
in K562 cells; GAPDH mRNA levels were comparable between the treatments (Fig3A). 
When LNCaP cells were treated with RSV, in the same manner, tensin mRNA levels 
increased as compared to the control, while GAPDH levels remained unchanged (Fig3B). 
This PCR was conducted in triplicate. The data indicate that RSV increases tensin mRNA 
levels in prostate cancer cells.  
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Figure 3. Expression of tensin in LNCaP cells with RSV treatment. Cells were incubated 
with indicated concentrations of RSV for 24hrs. RNA was extracted and RT PCR was 
performed. GAPDH was used as an endogenous control for RT PCR. PCR products were 
separated on 1% agarose gel and visualized under UV light. A) K562 cells were used as 
positive control for this experiment. They were treated with or without 100 M RSV. B) 
LNCaP cells were incubated with or without 50 M RSV. The PCR was conducted in 
triplicate.  
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RSV Affects Tensin mRNA Levels in LNCaP Cells Optimally at 50 M   
 
To further confirm effects of RSV on tensin mRNA levels in LNCaP cells, we 
treated LNCaP cells with various concentrations of RSV. Total RNA was purified and 
RT-PCR was performed. PCR products were separated on 1% agarose gel and visulized 
under UV light. As shown in Fig 4A, when LNCaP cells were treated with 10 M RSV 
tensin expression was upregulated compared to the control. Stronger increases were seen 
at 25 M and 50 M. However, at higher concentrations (100 M), we saw a decrease in 
expression. In addition, we saw a significant increase in the number of dead cells when 
treated at such high concentrations. To further visualize these results, ImageJ software 
was used to quantitate the data from Fig4A and numbers are shown in graphical analysis 
(Fig4B). Although it appears that tensin mRNA levels are increased with 10 M treatment 
of RSV, the significant effect was seen when cells were treated with 50 M (p<0.05).  
Therefore, we subsequently used 50 M for the rest of the experiments. 
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Figure 4: Tensin expression with various RSV concentrations. A) LNCaP cells were 
treated at various concentrations of RSV. RNA was extracted and RT PCR was 
performed in triplicate. GAPDH was used as an endogenous control for RT PCR. PCR 
products were separated on 1% agarose gel and visualized under UV light. B) Graphical 
presentation of Fig4A using ImageJ software. Same areas were measured for all bands 
and intensities of each area were quantified. GAPDH was used to normalize each band. 
The control was set as 1.  
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RSV Affects Tensin mRNA Levels in a Time-dependent Manner   
 
LNCaP cells were treated with 50 M RSV and samples were collected at 
different time points. Total RNA was purified and RT-PCR was performed. PCR 
products were separated on 1% agarose gel and visulized under UV light. As shown in 
Fig 5, the RSV effects on tensin mRNA levles were first seen at 12hrs and stronger 
effects were observed  with longer incubations. Thus, together with what we observed in 
Fig 4, RSV effects on tensin mRNA levels are dose- and time-dependent up to 48hrs.  
 
 
 
 
 
 
 
Figure 5: Time dependent effects of RSV on tensin mRNA levels. LNCaP cells were 
treated with 50 M RSV and collected at various time points. RNA was extracted and RT 
PCR was performed. GAPDH was used as an endogenous control for RT PCR. PCR 
products were separated on 1% agarose gel and visualized under UV light.  
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 RSV Counteracts Androgen-induced Downregulation of Tensin in LNCaP Cells 
 
It is well established that androgen functions through interaction with AR. The 
ligand-bounded receptor translocates into the nucleus and up- or down-regulates target 
gene expression. We were interested in determining whether the effects of RSV on tensin 
expression is through the function of AR. LNCaP cells were treated with either 50 M of 
RSV, 10 nM of androgen (R1881), or a combination of RSV (50 M) and R1881 (10nM). 
Total RNA was purified and RT-PCR was performed. PCR products were separated on 
1% agarose gel and visulized under UV light (Fig 6A). The results from Fig6A were then 
quantified using ImageJ software (Fig6B). Comparing to the control, when cells were 
treated with androgen, tensin mRNA levels were significantly down-regulated (p<0.05). 
This androgen-induced downregulation was significantly counteracted by RSV (p<0.05). 
It is well known that androgen functions through AR and tensin was down-regulated by 
androgen treatment. Because RSV counteracted this effect, it suggests that RSVs effects 
on tensin are mediated through the AR.  
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Figure 6: Effects of RSV and Androgen on tensin in LNCaP cells. A) LNCaP cells were 
treated with or without R1881 or RSV as well as in combination for 24 hours. RNA was 
extracted and RT PCR was performed in triplicate. B) Fig6A quantified using ImageJ 
software. The control was set as 1. 
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Confirmation of AR Expression in the AR(+) Cell Line 
In order to test the hypothesis that RSV increased tensin mRNA levels by a 
mechanism that involves AR, experiments were conducted using a cell line which stably  
overexpression of AR (Shi WF, Leong M et. al, PloS One, 2009 Oct 9; 4(10):e7398) (Shi 
et al., 2009) in parallel with the AR(-) parent cell line as a negative control. First, the 
Western blot was conducted with anti-AR antibodies using lysate from AR(+), AR(-); 
and LNCaP cell lysate was used as a control. The molecular weight of AR is ~110kD. A 
band around 110kD was seen in both AR(+) and LNCaP cell lysates, but not in that of 
AR(-).  
 
 
 
 
 
 
 
 
 
  
Figure 7:. Confirmation of AR expression in AR(+) cell line. Western Blot for 
confirmation of AR expression in AR(+) cell lines. Proteins (50 g) in whole cell lysate 
were subjected to SDS-PAGE, followed by Western Blot analysis with anti-AR antibody.  
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RSV Effect on Tensin Upregulation is at least partially AR-dependent 
It has been established previously that 100 M RSV was optimal for the AR(+) 
and AR(-) cell lines (Shi et al., 2009).  To examine the RSV effects on AR(+) cell lines, 
we treated all three cells, AR(+), AR(-) and K562, with 100 M of RSV for 24hrs. RT-
PCRs were conducted and GAPDH was used as an internal control and mRNA were 
comparable between the treatment and non-treatment.  Same as demonstrated in previous 
experiments, the RSV treatment upregulated tensin mRNA levels significantly in K562 
cells (Fig8).  The RSV effects on tensin mRNA levels were seen in the AR(+) cells, but 
not in AR(-) cells (Fig8).  
 
 
 
 
26 
 
 
Figure 8: Effects on RSV on tensin mRNA levels in AR(+) cells.  K562, AR(+), and AR(-) 
cells were treated with or without 100 M of RSV for 24 hours. RNA was extracted and 
RT PCR was performed in triplicate. GAPDH was used as an endogenous control for RT 
PCR. PCR products were separated on 1% agarose gel and visualized under UV light.  
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RSV Up-regulates Tensin mRNA Levels in a Time-dependent Manner up to 48hrs 
In order to further study RSV effects on tensin mRNA levels, AR(+) cells were 
treated with 100 M of RSV and collected at different time points. Total RNA was 
purified and RT-PCR was performed. As shown in Fig 9, RSV effects on tensin 
expression were seen as early as 6hrs and increased with longer treatments up to 24hrs. 
However, tensin levels appeared to become lower with longer incubations.  
 
 
 
 
 
Figure 9: Effects of RSV on tensin expression in a time dependent manner. AR(+) cells 
were treated with 100 M RSV and collected at different time points. RNA was extracted 
and RT PCR was performed. GAPDH was used as an endogenous control for RT PCR. 
PCR products were separated on 1% agarose gel and visualized under UV light. 
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RSV Counteracts Androgen-induced Downregulation of Tensin in AR (+) Cells 
 In order to further demonstrate that the effects of RSV on tensin mRNA levels are 
AR-dependent, we conducted an experiment that was designed similarly to that in Figure 
6. Total RNA was purified and the RSV effects on tensin were estimated by RT-PCR. As 
shown in Figure 10, when AR(+) cells were treated with 10nM of R1881, tensin mRNA 
levels were down-regulated as compared to the control. When AR(+) cells were treated 
with 100 M of RSV, tensin mRNA levels increased as compared to the control.  More 
importantly, when AR(+) cells were treated with both RSV (100 M) and R1881 (10nM), 
the androgen-induced downregulation of tensin mRNA was counteracted by RSV. 
However, none of these effects were observed in the AR(-) cell line. Because the only 
difference between these cell lines is the presence or absence of the androgen receptor, 
we conclude that the observed RSV effects on tensin mRNA levels are AR dependent. 
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Figure 10: RSV counteracts androgen-dependent downregulation of tensin in AR(+) 
cells. AR(+), and AR(-) cells were treated with or without R1881 or RSV as well as in 
combination for 18 hours. RNA was extracted and RT PCR was performed. GAPDH was 
used as an endogenous control for RT PCR. PCR products were separated on 1% agarose 
gel and visualized under UV light. 
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Expression of Tensin Protein Levels 
In order to examine the effects of RSV on tensin protein levels, LNCaP cells were 
treated with various concentrations of RSV for 24 hrs and whole cell lysates were 
separated on SDS-PAGE followed by western blot. A cell lysate containing tensin (Santa 
Cruz, Santa Cruz, CA) was used as a positive control. The bands in all treatments 
including the positive control were seen at the same molecular maker around 40kDa 
(Fig11A).  
The intact tensin molecule has been reported as a 220kDa protein.  However, it is 
a substrate of the calcium-dependent cysteine protease calpain II. Therefore, tensin is 
rapidly cleaved into several fragments, one of these cleavage products corresponds to the 
size of 40-45kDa. The bands we observed were around 40-45kD; therefore we used a 
calpain II inhibitor MDL in an attempt to preserve the intact tensin protein. LNCaP cells 
were treated with various concentrations of MDL and incubated for 16hrs. However, 
western blot shows that all bands were once again between 40-45kDa (Fig 11B).  
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Figure 11: Protein expression of tensin. A) LNCaP cells were treated with indicated 
concentrations of RSV for 24hrs. Proteins (20 g) in whole cell lysate were subjected to 
SDS-PAGE, followed by Western Blot analysis with anti-Tensin antibody. B) LNCaP 
cells were treated with indicated concentrations of MDL for 16hrs. Proteins (20 g) in 
whole cell lysate were subjected to SDS-PAGE, followed by Western Blot analysis with 
anti-Tensin antibody. 
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Discussion 
Despite advances in treatments and therapies, prostate cancer remains second only 
to lung cancer as the leading cause of cancer-related death in men (Seeni et al., 2008).  
Prostate cancers are unique in requiring androgens to maintain growth and avoid 
apoptosis. Therefore, androgen depletion combined with anti-androgenic agents is the 
initial recommended treatment for androgen-dependent prostate cancer (Shi et al., 2009). 
This treatment, while effective in about 80% of these cases, is not without its problems 
(OH, 2002). Hormone ablation treatments can have a negative impact on the quality of 
life in men. Several side effects include hot flashes, osteoporosis, anemia, fatigue, 
sarcopenia, gynecomastia and emotional distress as well as loss of libido and erectile 
dysfunction (Herr & O'Sullivan, 2000; Holzbeierlein et al., 2004; Nelson et al., 2008; 
Thompson et al., 2003). In addition there is increased risk of developing diabetes, 
cardiovascular disease and fatal cardiac events (Keating et al., 2006). There is also 
evidence suggesting that this treatment also impacts cognitive functioning. Cognitive 
deficits can impact a patient's ability to make informed treatment decisions, perform 
occupational or intellectual pursuits, and can have a negative impact on their overall 
quality of life (Herr & O'Sullivan, 2000; Holzbeierlein et al., 2004; Nelson et al., 2008; 
Thompson et al., 2003).  
While it is important to develop improved treatments for established cancers, 
another approach is to focus on chemoprevention. Epidemiological studies indicate that 
RSV enriched beverage consumption can significantly lower prostate cancer instance 
(Schoonen, Salinas, Kiemeney, & Stanford, 2005). RSV has also been recognized as a 
novel potential cancer chemopreventive agent in both animal and cell models (Seeni et 
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al., 2008). In 1999, Hsieh et al demonstrated that RSV inhibited the growth of LNCaP 
cells; additionally they used flow cytometric analysis to show that RSV induced 
apoptosis of these cells (Hsieh & Wu, 1999). RSV has also been shown to inhibit the 
PI3K/AKT pathway, which is responsible for cell growth and tumorigenesis. RSV 
enhances the therapeutic potential of Tumor Necrosis Factor Apoptosis (TRAIL) by up-
regulating death receptors, and engages in a mitochondrial pathway of apoptosis (Q. 
Chen et al., 2010). Additionally RSV has been found to induce the nuclear translocation 
of p53 and the expression of p53-responsive genes (Zheng et al., 2010).  
There have also been multiple animal studies with RSV, showing a number of 
anti-cancer activities that were recently summarized by Namasivayam, N. A few of the 
most well documented effects of RSV in animal studies include antioxidant effects, 
modulation of carcinogen metabolism, anti-inflammatory potential, antioxidant 
properties, antiproliferative mechanisms by induction of apoptosis, and cell 
differentiation with vast research on RSV as an anti-cancer agent (Namasivayam, 2011). 
While there is no published data of these RSV effects in humans, there are currently a 
number of clinical trials going on which are examining RSV’s effects on diseases such as 
diabetes, Alzheimer’s disease, and a number of cancers 
(http://clinicaltrials.gov/ct2/results?term=resveratrol). Hopefully, these trials will one day 
provide further information about RSV and its mechanism. 
It has been reported that RSV has inhibited the growth of androgen-responsive 
prostate cancer cells, in part by decreasing AR expression. In addition, there has been 
much research to show that down-regulation of AR and its target genes is not solely due 
to a decreased amount of AR, but RSV also decreases AR activity (Gao et al., 2004; 
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Jones et al., 2005). Even though the detailed mechanisms by which RSV inhibits AR 
function remains unclear, RSV seems to be a potentially important agent in the 
prevention of prostate cancer (Harada et al., 2011). Since RSV has proven to be an 
effective anti-cancer agent, researchers wanted to gain more knowledge about its target 
genes. In 2005, during a search to recognize such genes, it was found that tensin protein 
and gene expression levels were greatly increased by RSV in leukemia cells and breast 
cancer cells (Rodrigue et al., 2005).    
Tensin plays a role in cell proliferation and migration as well as closely associates 
with DLC-1. Because DLC-1 itself is a negative regulator of tumor formation and plays a 
role in cell migration, it has been suggested that tensin may play a role in tumor 
suppression and perhaps serve as a checkpoint in cell growth. Tensin expression is down-
regulated in several types of cancers, such as breast cancer and prostate cancer. (Lo, 
2004; Martuszewska et al., 2009).  Due to tensin’s normal function, a decrease in tensin 
expression might contribute to formation and/or progression of tumors. If RSV can 
maintain or restore normal levels of tensin, this may contribute to its chemopreventive 
and/or therapeutic effects.  
We have demonstrated that tensin mRNA levels are upregulated by RSV in 
LNCaP cells, an androgen dependent cancer cell line (Fig 3), and that this upregulation is 
dose- and time-dependent. Maximal effects at 50 M in LNCaP cells (Fig 4) and mRNA 
increases were seen as early as 6 hrs (Fig 5). In LNCaP cells, higher doses of RSV were 
less effective, and were associated with increased cell death (Fig 4). Additionally, it 
appears that prolonged incubation up to 48hrs enhances RSVs effect on tensin mRNA 
levels (Fig 5). There have been several findings of RSV causing increased cell death at 
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high concentrations and prolonged treatment. For example, Hsieh et al saw cell death by 
apoptosis in LNCaP cells beginning with 25 M RSV with a 4day treatment (Hsieh & 
Wu, 1999). In addition, Wang et al saw apoptosis of LNCaP cells beginning with 25 M 
RSV after only 24 hours (T. T. Wang et al., 2008). Additionally there have not been 
published reports confirming that high levels of RSV cause necrosis in LNCaP cells. 
However, preliminary data from our lab suggest these findings in other types of cancer 
cells. Using Annexin 5 labeling, it has been shown that at concentrations of RSV over 
100 M and up to 200 M, apoptosis that was seen at lower concentrations is no longer 
taking place in the oral cancer cell line Cal27 (personal communication). At these higher 
concentrations of RSV the cell membrane becomes leaky and is no longer intact, 
indicating that necrosis may be taking place. Due to these findings it is plausible to 
hypothesize that at higher concentrations of RSV the LNCaP cells may be undergoing 
necrosis. This being said, it was important during the course of this research to use RSV 
concentrations that were optimal for different cells lines. When working with LNCaP 
cells, 50 M RSV was used; AR(+), AR(-), and K562 cells were treated with 100 M. 
This ensured that the optimal results were achieved for each of the experiments that were 
carried out. 
 
In most cases, protein levels mirror mRNA levels. After observing the 
upregulation of tensin mRNA levels by RSV, we attempted to show the effects on protein 
levels. When we tried to measure tensin protein levels in LNCaP cells, we were unable to 
show tensin at the expected molecular weight of 220kD. This is consistent with the 
previous report that tensin protein was not detected in LNCaP cells (H. Chen et al., 
2000). However, bands were consistently seen between 40-45kD, even in a positive 
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control lysate (tensin) (Fig 11A). Chen et al reported that there are multiple cleavage sites 
on tensin by calpain II and one of the cleaved products is around 40kD. However, the 
biological significance of this cleavage is unknown.  
MDL is a membrane-permeable calpain II inhibitor (H. Chen et al., 2000).  We 
used different concentrations of MDL to treat LNCaP cells in order to show the 
undegraded tensin protein. However, this experiment was also inconclusive. We observed 
two bands, which appeared between 40kDa to 45kDa (Fig 11B). There are some possible 
explanations for this occurrence. First, calcium is needed for calpain II activity, and it is 
not known whether MDL can inhibit calpain II activity in the calcium levels present in 
the LNCaP cells. (H. Chen et al., 2000). While there most likely were not very high 
amounts of calcium present during our experiments, we did not measure calcium levels at 
the time of treatment. Some previous studies have hinted to this possible effect, however, 
we did not investigate this further. Second, tensin may be cleaved by other calcium-
dependent cysteine proteases like calpain II that interact with focal adhesion molecules 
(H. Chen et al., 2000). It has been reported that proteins similar to tensin are substrates 
for these calcium-dependent cysteine proteases. So far, the only known protease of this 
family to cleave tensin is calpain II (H. Chen et al., 2000).  It can be hypothesized that 
tensin may be a substrate for other calcium-dependent cysteine proteases and further 
experiments could be done using inhibitors of proteases in this family that may cleave 
tensin. Also, calcium levels should be monitored during all experiments, to ensure 
calpain II will not be active to cleave tensin.  
Based on previous evidence that RSV down-regulates AR expression and activity 
(Harada et al., 2011; Shi et al., 2009), further work was done with AR during our 
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research. LNCaP cells are androgen-dependent prostate cancer cells, AR in these cells is 
responsive to androgen. When cells were treated with R1881, a synthesized androgen, 
tensin mRNA levels decreased significantly (Fig 6). When cells were treated with RSV 
tensin mRNA levels increased. When cells were treated with a combination of R1881 and 
RSV, RSV significantly counteracted androgen’s effects on tensin. These results lead us 
to further examine a potential mechanism of RSV’s effects on tensin through AR.  To 
confirm that this effect is AR dependent, the AR(+) cell line was utilized in a series of 
experiments; and the AR(-) parent cell line serve as a negative control.  Similar to what 
we saw in LNCaP cells, tensin mRNA levels were down-regulated in AR(+) cells when 
treated with androgen and this effect was counteracted by RSV. However, these effects 
were not seen in AR(-) cells. Since the only difference between the AR(+) and AR(-) cell 
lines is the presence or absence of the androgen receptor, these results demonstrate 
unambiguously that the effects of RSV on tensin mRNA levels is AR-dependent. 
However, whether tensin is directly or indirectly regulated by AR is unknown.  
Data from previous reports indicate RSV’s effects on AR were not by affecting 
AR/heat shock protein interaction, nuclear translocation, or binding of AREs (Harada et 
al., 2011; Shi et al., 2009). It is likely that RSV affects AR activity by fine-tuning the 
ratios of transcriptional activators and repressors recruited by AR. These ratios will affect 
the histone code on the promoter of target genes and ultimately determine the expression 
of the targets (Fig12). The tensin promoter has not yet been identified, so it is not known 
whether there is an AR binding site on its promoter. To determine if RSV is up-regulating 
tensin directly through AR, the tensin promoter needs to be identified and possibly a 
Chromatin Immunoprecipitation (Chip) assay performed to confirm AR interactions. 
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Figure 12: Proposed model of RSV effects of AR target gene expression through 
modulating AR transcriptional activities. RSV may exert its effects on AR directly by 
affecting AR conformation, leading to subsequent alteration of the recruitment of one or 
more co-regulators. RSV may lead to alterations in (1) co-regulator recruitment, (2) 
histone code modification, and (3) transcriptional regulation.  
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Prostate cancer is generally categorized into two stages. The early stage is 
referred to as androgen-dependent and the late stage is referred to as androgen-
independent. However, AR is expressed and is functional in both stages. During the late 
stage, a variety of AR alterations include amplification, point mutation, and changes in 
expression of its co-regulatory proteins (Taplin & Balk, 2004). Since RSV affects AR 
activity, the results from our research indicate that RSV may be beneficial in both 
androgen-dependent and androgen-independent prostate cancers. It could be used as a 
chemopreventive agent to counteract androgens in the early stage, as well as a therapeutic 
agent in the late stage to interfere with AR directly.  
Given the increasing incidence of prostate cancer in the US, it is imperative to 
find better means to combat this disease. Although many targets of RSV have been 
identified in the past, the identification of tensin as another target has added a new 
dimension in this research area. Since tensin is down-regulated in cancers including 
prostate cancers, up-regulating tensin by RSV could be one of the strategies in cancer 
prevention and therapy.  
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